Entasis Therapeutics Holdings Inc. (ETTX) experienced an increase of 13.10% in premarket following the updates in SEC filing. However, the last trading session closed at $1.45 with a decrease of 1.36%.
Third Quarter 2021 Financial results by ETTX
ETTX announced third quarter 2021 financial results on 4th November 2021. The company experienced a net loss of $12.4 million with research and development costs of $9.3 million. Moreover, the general and administrative expenses were $4.3 million with research and development costs around $9.3 million. Last but not the least, cash and cash equivalents came out to be $44.1 million.
Now what?
The publication of topline results from the landmark Phase 3 ATTACK study in patients with Acinetobacter infections, where SUL-DUR accomplished all direct and indirect endpoints, was a thrilling era for Entasis. Moreover, SUL-DUR is the first investigational medicine to show efficacy in 28-day all-cause mortality in this patient population, as well as clinical cure rates and safety. Furthermore, the findings suggest that SUL-DUR could be a potentially life-saving treatment for patients with Acinetobacter infections, despite the fact that incremental gains have long been the standard in this field.
In preparation for the NDA application in mid-2022, ETTX is excited to discuss the data with regulatory agencies. The company also intensified the commercial preparedness activities for SUL-DUR over the last quarter, with the appointment of Anna Diaz Triola as the Chief Commercial Officer to lead the charge. Finally, ETTX is making progress on the rest of the pipeline, with the most recent candidate ETX0462 being published in the prominent magazine Nature. Last but not the least, ETX0462 is the first of a new class of antibiotics that has activity against a wide range of Gram-negative infections, including Pseudomonas aeruginosa and a number of high-priority biothreat diseases.
Positive Topline Results for Sulbactam-Durlobactam by ETTX
ETTX announced positive results for Sulbactam-Durlobactam on 19th October 2021. New antibiotics are needed by doctors and patients to combat drug-resistant germs. Moreover, Acinetobacter infections are among the hardest to treat, using a significant amount of healthcare resources while causing pain and suffering to patients. The ATTACK study results are robust and intriguing, revealing great safety and efficacy results as well as favorable and substantial clinical cure rates.
